美国对基于实证的长寿解决方案展现出无可比拟的规模与需求。Deep Longevity 经临床验证的深度老化 时钟 - 包括BloodAge、MindAge、BiometricAge、 EpigeneticAge及即将推出的FaceAge - 提供远超过时 序年龄的精准且多维度的生物年龄评估。该等工具赋予消费者、医生、雇主及保险公司可执行及个人化 的洞察力，以延长健康寿命并延缓老化。 智通财经APP讯，励晶太平洋(00575)发布公告，全球可解释人工智能驱动老化时钟与长寿科学的领导者 Deep Longevity, Inc及其附属公司(统称Deep Longevity)将于2026年第一季度启动进军美利坚合众国(美国) 的扩张计划。此举将使Deep Longevity挤身于全球规模最大且增长最迅速的健康市场核心，该市场当前 估值逾6.8万亿美元。 Deep Longevity的技术已获得数十篇同行评审论文及多项授权专利的支持。其多模态老化时钟整合血液 生物标志物、表观遗传学、心理学、生物学，及将整合的面部成像以提供当今最全面的生物老化画像。 为推动快速普及，Deep Longevity正组建美国本土销售团队，首 ...

Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].